192 related articles for article (PubMed ID: 27909986)
1. Toxicity and Pharmacokinetic Profile for Single-Dose Injection of ABY-029: a Fluorescent Anti-EGFR Synthetic Affibody Molecule for Human Use.
Samkoe KS; Gunn JR; Marra K; Hull SM; Moodie KL; Feldwisch J; Strong TV; Draney DR; Hoopes PJ; Roberts DW; Paulsen K; Pogue BW
Mol Imaging Biol; 2017 Aug; 19(4):512-521. PubMed ID: 27909986
[TBL] [Abstract][Full Text] [Related]
2. Fluorescent Affibody Molecule Administered In Vivo at a Microdose Level Labels EGFR Expressing Glioma Tumor Regions.
de Souza AL; Marra K; Gunn J; Samkoe KS; Hoopes PJ; Feldwisch J; Paulsen KD; Pogue BW
Mol Imaging Biol; 2017 Feb; 19(1):41-48. PubMed ID: 27379987
[TBL] [Abstract][Full Text] [Related]
3. Identification of a Suitable Untargeted Agent for the Clinical Translation of ABY-029 Paired-Agent Imaging in Fluorescence-Guided Surgery.
Wang C; Xu X; Hodge S; Chen EY; Hoopes PJ; Tichauer KM; Samkoe KS
Mol Imaging Biol; 2023 Feb; 25(1):97-109. PubMed ID: 34642897
[TBL] [Abstract][Full Text] [Related]
4. Optimizing Glioma Detection Using an EGFR-Targeted Fluorescent Affibody.
Ribeiro de Souza AL; Marra K; Gunn J; Samkoe KS; Hull S; Paulsen KD; Pogue BW
Photochem Photobiol; 2018 Nov; 94(6):1167-1171. PubMed ID: 30129069
[TBL] [Abstract][Full Text] [Related]
5. Preclinical imaging of epidermal growth factor receptor with ABY-029 in soft-tissue sarcoma for fluorescence-guided surgery and tumor detection.
Samkoe KS; Sardar HS; Bates BD; Tselepidakis NN; Gunn JR; Hoffer-Hawlik KA; Feldwisch J; Pogue BW; Paulsen KD; Henderson ER
J Surg Oncol; 2019 Jun; 119(8):1077-1086. PubMed ID: 30950072
[TBL] [Abstract][Full Text] [Related]
6. Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold.
Ahlgren S; Orlova A; Wållberg H; Hansson M; Sandström M; Lewsley R; Wennborg A; Abrahmsén L; Tolmachev V; Feldwisch J
J Nucl Med; 2010 Jul; 51(7):1131-8. PubMed ID: 20554729
[TBL] [Abstract][Full Text] [Related]
7. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
[TBL] [Abstract][Full Text] [Related]
8. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule.
Sörensen J; Sandberg D; Sandström M; Wennborg A; Feldwisch J; Tolmachev V; Åström G; Lubberink M; Garske-Román U; Carlsson J; Lindman H
J Nucl Med; 2014 May; 55(5):730-5. PubMed ID: 24665085
[TBL] [Abstract][Full Text] [Related]
9. Perspectives on the Phase 0 clinical trial of microdose administration of ABY-029 for fluorescence guided surgery: Stability testing.
Samkoe KS; Hull S; Elliott J; Sardar HS; Gunn J; Linos K; Tafe L; Harris B; Feldwisch J; Pogue BW; Roberts D; Henderson E; Paydarfar J; Paulsen K
Proc SPIE Int Soc Opt Eng; 2020 Feb; 11222():. PubMed ID: 36051445
[TBL] [Abstract][Full Text] [Related]
10. Improved Discrimination of Tumors with Low and Heterogeneous EGFR Expression in Fluorescence-Guided Surgery Through Paired-Agent Protocols.
Wang C; Xu X; Folaron M; Gunn JR; Hodge S; Chen EY; Hoopes PJ; Tichauer KM; Samkoe KS
Mol Imaging Biol; 2023 Feb; 25(1):110-121. PubMed ID: 34651290
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Therapies Do Not Reduce Epidermal Growth Factor Receptor (EGFR) Expression or EGFR-Targeted Fluorescence in a Murine Model of Soft-Tissue Sarcomas.
Streeter SS; Xu X; Hebert KA; Werth PM; Hoopes PJ; Jarvis LA; Pogue BW; Paulsen KD; Samkoe KS; Henderson ER
Mol Imaging Biol; 2024 Apr; 26(2):272-283. PubMed ID: 38151580
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients.
Sandström M; Lindskog K; Velikyan I; Wennborg A; Feldwisch J; Sandberg D; Tolmachev V; Orlova A; Sörensen J; Carlsson J; Lindman H; Lubberink M
J Nucl Med; 2016 Jun; 57(6):867-71. PubMed ID: 26912439
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of four affibody-based near-infrared fluorescent probes for optical imaging of epidermal growth factor receptor positive tumors.
Qi S; Miao Z; Liu H; Xu Y; Feng Y; Cheng Z
Bioconjug Chem; 2012 Jun; 23(6):1149-56. PubMed ID: 22621238
[TBL] [Abstract][Full Text] [Related]
14. Single-dose intravenous toxicity study of IRDye 800CW in Sprague-Dawley rats.
Marshall MV; Draney D; Sevick-Muraca EM; Olive DM
Mol Imaging Biol; 2010 Dec; 12(6):583-94. PubMed ID: 20376568
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous
Elliott JT; Marra K; Evans LT; Davis SC; Samkoe KS; Feldwisch J; Paulsen KD; Roberts DW; Pogue BW
Clin Cancer Res; 2017 May; 23(9):2203-2212. PubMed ID: 27799250
[No Abstract] [Full Text] [Related]
16. Cy5.5-labeled Affibody molecule for near-infrared fluorescent optical imaging of epidermal growth factor receptor positive tumors.
Miao Z; Ren G; Liu H; Jiang L; Cheng Z
J Biomed Opt; 2010; 15(3):036007. PubMed ID: 20615009
[TBL] [Abstract][Full Text] [Related]
17. Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate.
Tolmachev V; Feldwisch J; Lindborg M; Baastrup B; Sandström M; Orlova A
Nucl Med Biol; 2011 Jul; 38(5):697-706. PubMed ID: 21718945
[TBL] [Abstract][Full Text] [Related]
18. Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT.
Sandberg D; Tolmachev V; Velikyan I; Olofsson H; Wennborg A; Feldwisch J; Carlsson J; Lindman H; Sörensen J
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1337-1346. PubMed ID: 28261749
[TBL] [Abstract][Full Text] [Related]
19. Measuring microdose ABY-029 fluorescence signal in a primary human soft-tissue sarcoma resection.
Samkoe KS; Sardar HS; Gunn J; Feldwisch J; Linos K; Henderson E; Pogue B; Paulsen K
Proc SPIE Int Soc Opt Eng; 2019 Feb; 10862():. PubMed ID: 31595101
[TBL] [Abstract][Full Text] [Related]
20. Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody.
Malmberg J; Sandström M; Wester K; Tolmachev V; Orlova A
Nucl Med Biol; 2011 Nov; 38(8):1093-102. PubMed ID: 22137850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
